Nuklearmedizin 2019; 58(02): 113-114
DOI: 10.1055/s-0039-1683496
Vorträge
Demenz und Neuroonkologie
Georg Thieme Verlag KG Stuttgart · New York

TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study

M Unterrainer
1   LMU München, Nuklearmedizin, München
,
DF Fleischmann
2   LMU München, Strahlentherapie, München
,
F Vettermann
1   LMU München, Nuklearmedizin, München
,
V Ruf
3   LMU München, Neuropathologie, München
,
L Kaiser
1   LMU München, Nuklearmedizin, München
,
D Nelwan
1   LMU München, Nuklearmedizin, München
,
S Lindner
1   LMU München, Nuklearmedizin, München
,
M Brendel
1   LMU München, Nuklearmedizin, München
,
V Wenter
1   LMU München, Nuklearmedizin, München
,
S Stöcklein
4   LMU München, Radiologie, München
,
J Herms
3   LMU München, Neuropathologie, München
,
V Milenkovic
5   Universität Regensburg, Psychiatrie, Regensburg
,
R Rupprecht
5   Universität Regensburg, Psychiatrie, Regensburg
,
JC Tonn
6   LMU München, Neurochirurgie, München
,
C Belka
2   LMU München, Strahlentherapie, München
,
P Bartenstein
1   LMU München, Nuklearmedizin, München
,
M Niyazi
2   LMU München, Strahlentherapie, München
,
NL Albert
1   LMU München, Nuklearmedizin, München
› Author Affiliations
Further Information

Publication History

Publication Date:
27 March 2019 (online)

Also available ateRef
 

Ziel/Aim:

The 18kDa translocator protein (TSPO) is overexpressed in brain tumours. 18F-GE-180, a novel TSPO-ligand, has shown a high target-to-background contrast in glioblastoma. However, the association with the tumoral histology and molecular genetic features is still unknown. Therefore, we correlated uptake characteristics in 18F-GE-180 PET with the individual histological tumour grade and molecular genetic features.

Methodik/Methods:

57 patients with histologically verified glioma were included and underwent 18F-GE-180 PET; here the maximal/mean tumour-to-background ratios (TBRmax/TBRmean) were assessed. Uptake characteristics and neuropathological parameters were correlated (i.e. grading, IDH-mutation, MGMT-methylation and TERT-promoter-mutation).

Ergebnisse/Results:

IDH-mutation was present in 18/57 cases, 39/57 were classified as IDH-wildtype (5/57 WHO grade II, 16/57 grade III, 36/57 grade IV). High 18F-GE-180-uptake was observed in all but 3 cases (diffuse astrocytoma, WHO grade II). Comparing IDH-wildtype and IDH-mutant gliomas, uptake intensity (TBRmax 6.40 ± 2.33 vs. 5.58 ± 2.98, p = 0.140) was statistically indifferent. Comparing histological grading, WHO grade IV gliomas showed the highest uptake intensity (TBRmax 7.08 ± 2.12 vs. 5.12 ± 2.52 vs. 2.51 ± 1.27, p < 0.001) compared to WHO grade III/II gliomas. The same was observed in the subgroup of IDH-wildtype gliomas (TBRmax 6.92 ± 2.07 vs. 5.28 ± 1.92 vs. 1.72 ± 0.33, p = 0.017) and IDH-mutant gliomas (TBRmax 8.07 ± 2.35 vs. 5.02 ± 2.92 vs. 3.04 ± 1.45, p = 0.037). The same results were obtained for TBRmean. Regarding MGMT and TERT, no influence on uptake in PET was observed (p > 0.05 each).

Schlussfolgerungen/Conclusions:

Uptake in 18F-GE-180 PET is primarily associated with histological grading in contrast to the molecular genetic features. As high-grade gliomas show distinctly increased uptake, this imaging modality might be of clinical interest for planning of biopsy, resection and radiotherapy.